AstraZeneca's diabetes drug Farxiga nabs coveted kidney disease nod, way ahead of rival Jardiance

AstraZeneca's diabetes med Farxiga stormed the heart failure market with a first-in-class approval last year—and in chronic kidney disease, it just left would-be rival Jardiance in the dust.

The FDA late Friday approved Farxiga, also known as dapagliflozin, to treat chronic kidney disease even in patients without diabetes.